JP2006526581A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2006526581A5 JP2006526581A5 JP2006508134A JP2006508134A JP2006526581A5 JP 2006526581 A5 JP2006526581 A5 JP 2006526581A5 JP 2006508134 A JP2006508134 A JP 2006508134A JP 2006508134 A JP2006508134 A JP 2006508134A JP 2006526581 A5 JP2006526581 A5 JP 2006526581A5
- Authority
- JP
- Japan
- Prior art keywords
- phenyl
- nhr
- oxazin
- alkoxy
- thia
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims description 14
- 206010020649 Hyperkeratosis Diseases 0.000 claims description 11
- 239000000203 mixture Substances 0.000 claims description 7
- 208000002874 Acne Vulgaris Diseases 0.000 claims description 6
- 206010061218 Inflammation Diseases 0.000 claims description 6
- 206010000496 acne Diseases 0.000 claims description 6
- 230000004054 inflammatory process Effects 0.000 claims description 6
- 208000003643 Callosities Diseases 0.000 claims description 5
- 208000003251 Pruritus Diseases 0.000 claims description 5
- 239000002537 cosmetic Substances 0.000 claims description 4
- 230000002500 effect on skin Effects 0.000 claims description 4
- 206010012438 Dermatitis atopic Diseases 0.000 claims description 3
- 201000008937 atopic dermatitis Diseases 0.000 claims description 3
- 230000002265 prevention Effects 0.000 claims description 2
- 229910052736 halogen Inorganic materials 0.000 claims 20
- 150000002367 halogens Chemical class 0.000 claims 16
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 14
- 125000003118 aryl group Chemical group 0.000 claims 13
- 125000001072 heteroaryl group Chemical group 0.000 claims 13
- -1 trifluoromethoxy, carbamoyl Chemical group 0.000 claims 13
- 125000006700 (C1-C6) alkylthio group Chemical group 0.000 claims 10
- 125000004104 aryloxy group Chemical group 0.000 claims 10
- 125000005553 heteroaryloxy group Chemical group 0.000 claims 10
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 9
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 claims 8
- 125000003545 alkoxy group Chemical group 0.000 claims 7
- 125000005037 alkyl phenyl group Chemical group 0.000 claims 7
- 125000004429 atom Chemical group 0.000 claims 7
- 150000003536 tetrazoles Chemical class 0.000 claims 7
- 125000005842 heteroatom Chemical group 0.000 claims 6
- 208000017520 skin disease Diseases 0.000 claims 6
- 208000001126 Keratosis Diseases 0.000 claims 5
- 239000011148 porous material Substances 0.000 claims 5
- 150000003839 salts Chemical class 0.000 claims 5
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims 4
- 125000005843 halogen group Chemical group 0.000 claims 4
- 125000001424 substituent group Chemical group 0.000 claims 4
- 101100294115 Caenorhabditis elegans nhr-4 gene Proteins 0.000 claims 3
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims 3
- 229910052757 nitrogen Inorganic materials 0.000 claims 3
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 3
- 125000000547 substituted alkyl group Chemical group 0.000 claims 3
- PARCNSWPSDLQOG-UHFFFAOYSA-N 2-(2-chloro-4-nitrophenyl)-6,7-dimethoxy-3,1-benzoxazin-4-one Chemical compound O1C(=O)C=2C=C(OC)C(OC)=CC=2N=C1C1=CC=C([N+]([O-])=O)C=C1Cl PARCNSWPSDLQOG-UHFFFAOYSA-N 0.000 claims 2
- PGSUTFYUMAINFQ-UHFFFAOYSA-N 2-(2-chlorophenyl)-6,7-dimethoxy-3,1-benzoxazin-4-one Chemical compound O1C(=O)C=2C=C(OC)C(OC)=CC=2N=C1C1=CC=CC=C1Cl PGSUTFYUMAINFQ-UHFFFAOYSA-N 0.000 claims 2
- RVSYWOORIBXTII-UHFFFAOYSA-N 2-(2-chlorophenyl)thieno[3,2-d][1,3]oxazin-4-one Chemical compound ClC1=CC=CC=C1C(OC1=O)=NC2=C1SC=C2 RVSYWOORIBXTII-UHFFFAOYSA-N 0.000 claims 2
- HDQZJWISFBAGPN-UHFFFAOYSA-N 2-(2-fluorophenyl)-5,6,7,8-tetrahydro-[1]benzothiolo[2,3-d][1,3]oxazin-4-one Chemical compound FC1=CC=CC=C1C(OC1=O)=NC2=C1C(CCCC1)=C1S2 HDQZJWISFBAGPN-UHFFFAOYSA-N 0.000 claims 2
- FPVVYTVVOHLHAI-UHFFFAOYSA-N 2-(2-fluorophenyl)-6,7-dimethoxy-3,1-benzoxazin-4-one Chemical compound O1C(=O)C=2C=C(OC)C(OC)=CC=2N=C1C1=CC=CC=C1F FPVVYTVVOHLHAI-UHFFFAOYSA-N 0.000 claims 2
- HKRJBRGRGFMQJI-UHFFFAOYSA-N 2-(2-iodophenyl)-6,7-dimethoxy-3,1-benzoxazin-4-one Chemical compound O1C(=O)C=2C=C(OC)C(OC)=CC=2N=C1C1=CC=CC=C1I HKRJBRGRGFMQJI-UHFFFAOYSA-N 0.000 claims 2
- DRANOUSHAHFNNU-UHFFFAOYSA-N 2-(2-methoxyphenyl)-5,6,7,8-tetrahydro-[1]benzothiolo[2,3-d][1,3]oxazin-4-one Chemical compound COC1=CC=CC=C1C(OC1=O)=NC2=C1C(CCCC1)=C1S2 DRANOUSHAHFNNU-UHFFFAOYSA-N 0.000 claims 2
- WCCHLKANERBZME-UHFFFAOYSA-N 2-phenyl-5,6,7,8-tetrahydro-[1]benzothiolo[2,3-d][1,3]oxazin-4-one Chemical compound N=1C=2SC=3CCCCC=3C=2C(=O)OC=1C1=CC=CC=C1 WCCHLKANERBZME-UHFFFAOYSA-N 0.000 claims 2
- NQQHAYQNGIKJGS-UHFFFAOYSA-N 3-(2-chlorophenyl)-7,8-dihydro-6h-cyclopenta[2,3]thieno[2,4-b][1,3]oxazin-1-one Chemical compound ClC1=CC=CC=C1C(OC1=O)=NC2=C1C(CCC1)=C1S2 NQQHAYQNGIKJGS-UHFFFAOYSA-N 0.000 claims 2
- BAWKOFLWHIEYNR-UHFFFAOYSA-N 3-(4-fluorophenyl)-7,8-dihydro-6h-cyclopenta[2,3]thieno[2,4-b][1,3]oxazin-1-one Chemical compound C1=CC(F)=CC=C1C(OC1=O)=NC2=C1C(CCC1)=C1S2 BAWKOFLWHIEYNR-UHFFFAOYSA-N 0.000 claims 2
- IKFYXJIKWKRNCL-UHFFFAOYSA-N 3-(furan-2-yl)-7,8-dihydro-6h-cyclopenta[2,3]thieno[2,4-b][1,3]oxazin-1-one Chemical compound N=1C=2SC=3CCCC=3C=2C(=O)OC=1C1=CC=CO1 IKFYXJIKWKRNCL-UHFFFAOYSA-N 0.000 claims 2
- GGSPMVSSOMZWMD-UHFFFAOYSA-N 3-phenyl-7,8-dihydro-6h-cyclopenta[2,3]thieno[2,4-b][1,3]oxazin-1-one Chemical compound N=1C=2SC=3CCCC=3C=2C(=O)OC=1C1=CC=CC=C1 GGSPMVSSOMZWMD-UHFFFAOYSA-N 0.000 claims 2
- BRMARZZSMYAONH-UHFFFAOYSA-N 6-ethyl-2-(2-fluorophenyl)thieno[2,3-d][1,3]oxazin-4-one Chemical compound S1C(CC)=CC(C(O2)=O)=C1N=C2C1=CC=CC=C1F BRMARZZSMYAONH-UHFFFAOYSA-N 0.000 claims 2
- YQWJALSURRKLTN-UHFFFAOYSA-N 6-ethyl-2-(2-methylphenyl)thieno[2,3-d][1,3]oxazin-4-one Chemical compound S1C(CC)=CC(C(O2)=O)=C1N=C2C1=CC=CC=C1C YQWJALSURRKLTN-UHFFFAOYSA-N 0.000 claims 2
- NBIGHQYFPFWWON-UHFFFAOYSA-N 6-ethyl-2-(4-fluorophenyl)thieno[2,3-d][1,3]oxazin-4-one Chemical compound S1C(CC)=CC(C(O2)=O)=C1N=C2C1=CC=C(F)C=C1 NBIGHQYFPFWWON-UHFFFAOYSA-N 0.000 claims 2
- PXNUGROUEJRSQG-UHFFFAOYSA-N 6-methyl-2-naphthalen-1-ylthieno[2,3-d][1,3]oxazin-4-one Chemical compound C1=CC=C2C(C3=NC4=C(C(O3)=O)C=C(S4)C)=CC=CC2=C1 PXNUGROUEJRSQG-UHFFFAOYSA-N 0.000 claims 2
- ZRBLGTMUYZEIPC-UHFFFAOYSA-N 7-chloro-2-thiophen-2-yl-3,1-benzoxazin-4-one Chemical compound C=1C(Cl)=CC=C(C(O2)=O)C=1N=C2C1=CC=CS1 ZRBLGTMUYZEIPC-UHFFFAOYSA-N 0.000 claims 2
- 201000004624 Dermatitis Diseases 0.000 claims 2
- 206010012442 Dermatitis contact Diseases 0.000 claims 2
- 208000019028 Epidermal thickening Diseases 0.000 claims 2
- 208000010668 atopic eczema Diseases 0.000 claims 2
- 208000010247 contact dermatitis Diseases 0.000 claims 2
- VLQPTWRGZFDXMO-UHFFFAOYSA-N inden-4-one Chemical compound O=C1C=CC=C2C=CC=C12 VLQPTWRGZFDXMO-UHFFFAOYSA-N 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 125000001637 1-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C(*)=C([H])C([H])=C([H])C2=C1[H] 0.000 claims 1
- PVPUVIHHXSLIRC-UHFFFAOYSA-N 2-(3-methoxyphenyl)-5,6,7,8-tetrahydro-[1]benzothiolo[2,3-d][1,3]oxazin-4-one Chemical compound COC1=CC=CC(C=2OC(=O)C=3C=4CCCCC=4SC=3N=2)=C1 PVPUVIHHXSLIRC-UHFFFAOYSA-N 0.000 claims 1
- KINHAYQGYGHGHH-UHFFFAOYSA-N 2-(4-bromophenyl)-6-ethylthieno[2,3-d][1,3]oxazin-4-one Chemical compound S1C(CC)=CC(C(O2)=O)=C1N=C2C1=CC=C(Br)C=C1 KINHAYQGYGHGHH-UHFFFAOYSA-N 0.000 claims 1
- WAESZBXXLFRQBF-UHFFFAOYSA-N 2-(4-fluorophenyl)thieno[3,2-d][1,3]oxazin-4-one Chemical compound C1=CC(F)=CC=C1C(OC1=O)=NC2=C1SC=C2 WAESZBXXLFRQBF-UHFFFAOYSA-N 0.000 claims 1
- FIXJBNHERODWGA-UHFFFAOYSA-N 2-(furan-2-yl)-5,6-dimethylthieno[2,3-d][1,3]oxazin-4-one Chemical compound O1C(=O)C=2C(C)=C(C)SC=2N=C1C1=CC=CO1 FIXJBNHERODWGA-UHFFFAOYSA-N 0.000 claims 1
- 125000002941 2-furyl group Chemical group O1C([*])=C([H])C([H])=C1[H] 0.000 claims 1
- RTADOEPOCKJLSI-UHFFFAOYSA-N 2-naphthalen-1-yl-5,6,7,8-tetrahydro-[1]benzothiolo[2,3-d][1,3]oxazin-4-one Chemical compound C1=CC=C2C(C=3OC(C=4C=5CCCCC=5SC=4N=3)=O)=CC=CC2=C1 RTADOEPOCKJLSI-UHFFFAOYSA-N 0.000 claims 1
- DWKOESBNQVDIFB-UHFFFAOYSA-N 2-phenylthieno[3,2-d][1,3]oxazin-4-one Chemical compound N=1C=2C=CSC=2C(=O)OC=1C1=CC=CC=C1 DWKOESBNQVDIFB-UHFFFAOYSA-N 0.000 claims 1
- VJUYJIMTTPMGKQ-UHFFFAOYSA-N 2-pyridin-4-yl-6,7,8,9-tetrahydro-5h-cyclohepta[2,3]thieno[2,4-b][1,3]oxazin-4-one Chemical compound N=1C=2SC=3CCCCCC=3C=2C(=O)OC=1C1=CC=NC=C1 VJUYJIMTTPMGKQ-UHFFFAOYSA-N 0.000 claims 1
- 125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 claims 1
- NLIOCPWLMFTKMV-UHFFFAOYSA-N 2-thiophen-2-yl-5,6,7,8-tetrahydro-[1]benzothiolo[2,3-d][1,3]oxazin-4-one Chemical compound N=1C=2SC=3CCCCC=3C=2C(=O)OC=1C1=CC=CS1 NLIOCPWLMFTKMV-UHFFFAOYSA-N 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- 239000006071 cream Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000000499 gel Substances 0.000 claims 1
- 239000000865 liniment Substances 0.000 claims 1
- 229940040145 liniment Drugs 0.000 claims 1
- 239000006210 lotion Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000002674 ointment Substances 0.000 claims 1
- 239000006072 paste Substances 0.000 claims 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- 239000000843 powder Substances 0.000 claims 1
- 239000002453 shampoo Substances 0.000 claims 1
- 239000000344 soap Substances 0.000 claims 1
- 239000007921 spray Substances 0.000 claims 1
- 238000011200 topical administration Methods 0.000 claims 1
- 241000699660 Mus musculus Species 0.000 description 4
- 238000011830 transgenic mouse model Methods 0.000 description 4
- 230000003902 lesion Effects 0.000 description 2
- 206010013786 Dry skin Diseases 0.000 description 1
- 101001091388 Homo sapiens Kallikrein-7 Proteins 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 210000000270 basal cell Anatomy 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000037336 dry skin Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 102000055383 human KLK7 Human genes 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000001185 psoriatic effect Effects 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 230000005068 transpiration Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA200300843 | 2003-06-06 | ||
| DKPA200300842 | 2003-06-06 | ||
| DKPA200300844 | 2003-06-06 | ||
| DKPA200300844 | 2003-06-06 | ||
| DKPA200300840 | 2003-06-06 | ||
| DKPA200300840 | 2003-06-06 | ||
| DKPA200300842 | 2003-06-06 | ||
| DKPA200300843 | 2003-06-06 | ||
| PCT/DK2004/000388 WO2004108139A2 (en) | 2003-06-06 | 2004-06-07 | Use of fused heterocyclic compounds as scce inhibitors for the treatment of skin conditions or cancer |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2006526581A JP2006526581A (ja) | 2006-11-24 |
| JP2006526581A5 true JP2006526581A5 (enExample) | 2011-05-26 |
| JP5044214B2 JP5044214B2 (ja) | 2012-10-10 |
Family
ID=33514772
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006508134A Expired - Fee Related JP5044214B2 (ja) | 2003-06-06 | 2004-06-07 | 皮膚状態または癌の処置のためのｓｃｃｅ阻害剤としての縮合複素環化合物の使用 |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US7872052B2 (enExample) |
| EP (1) | EP1631295B1 (enExample) |
| JP (1) | JP5044214B2 (enExample) |
| KR (2) | KR101205257B1 (enExample) |
| CN (1) | CN101152185B (enExample) |
| AT (1) | ATE459359T1 (enExample) |
| CA (1) | CA2525383C (enExample) |
| CY (1) | CY1110084T1 (enExample) |
| DE (1) | DE602004025803D1 (enExample) |
| DK (1) | DK1631295T3 (enExample) |
| ES (1) | ES2341545T3 (enExample) |
| NO (1) | NO20060091L (enExample) |
| NZ (1) | NZ543636A (enExample) |
| PL (1) | PL1631295T3 (enExample) |
| PT (1) | PT1631295E (enExample) |
| SI (1) | SI1631295T1 (enExample) |
| WO (1) | WO2004108139A2 (enExample) |
Families Citing this family (68)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10238724A1 (de) | 2002-08-23 | 2004-03-04 | Bayer Ag | Alkyl-substituierte Pyrazolpyrimidine |
| DE10238722A1 (de) | 2002-08-23 | 2004-03-11 | Bayer Ag | Selektive Phosphodiesterase 9A-Inhibitoren als Arzneimittel zur Verbesserung kognitiver Prozesse |
| US8044060B2 (en) | 2003-05-09 | 2011-10-25 | Boehringer Ingelheim International Gmbh | 6-cyclylmethyl- and 6-alkylmethyl pyrazolo[3,4-D]pyrimidines, methods for their preparation and methods for their use to treat impairments of perception, concentration learning and/or memory |
| DE10320785A1 (de) * | 2003-05-09 | 2004-11-25 | Bayer Healthcare Ag | 6-Arylmethyl-substituierte Pyrazolopyrimidine |
| DE102004001873A1 (de) * | 2004-01-14 | 2005-09-29 | Bayer Healthcare Ag | Cyanopyrimidinone |
| WO2007016525A2 (en) * | 2005-07-29 | 2007-02-08 | Resverlogix Corp. | Pharmaceutical compositions for the prevention and treatment of complex diseases and their delivery by insertable medical devices |
| PL2066662T3 (pl) | 2006-09-21 | 2013-05-31 | Kyorin Seiyaku Kk | Inhibitory hydrolaz serynowych |
| KR101129868B1 (ko) | 2006-10-04 | 2012-04-12 | 화이자 프로덕츠 인코포레이티드 | 칼슘 수용체 길항제로서의 피리도［4,3-ｄ］피리미딘-4(3Ｈ)-온 유도체 |
| JP5236664B2 (ja) | 2007-02-01 | 2013-07-17 | レスバーロジックス コーポレイション | 心血管疾患を予防および治療するための化合物 |
| JP5520824B2 (ja) | 2007-08-17 | 2014-06-11 | ノバルティス アーゲー | 環状デプシペプチド類 |
| EP2183270B1 (en) * | 2007-08-17 | 2014-12-17 | Novartis AG | Use of cyclic depsipeptides to inhibit kallikrein 7 |
| US8648085B2 (en) | 2007-11-30 | 2014-02-11 | Boehringer Ingelheim International Gmbh | 1, 5-dihydro-pyrazolo (3, 4-D) pyrimidin-4-one derivatives and their use as PDE9A mudulators for the treatment of CNS disorders |
| UA105362C2 (en) | 2008-04-02 | 2014-05-12 | Бьорингер Ингельхайм Интернациональ Гмбх | 1-heterocyclyl-1, 5-dihydro-pyrazolo [3, 4-d] pyrimidin-4-one derivatives and their use as pde9a modulators |
| BRPI0918527A2 (pt) | 2008-09-08 | 2015-12-01 | Boehring Ingelheim Internat Gmbh | compostos para o tratamento de disturbios do cns |
| EP2660238B1 (en) | 2009-01-08 | 2015-05-06 | Resverlogix Corporation | Compounds for the prevention and treatment of cardiovascular disease |
| US8691828B2 (en) * | 2009-03-05 | 2014-04-08 | Takeda Pharmaceutical Company Limited | Thienopyrimidine as CDC7 kinase inhibitors |
| MX392179B (es) | 2009-03-18 | 2025-03-21 | Resverlogix Corp | Nuevos agentes anti-inflamatorios. |
| AU2010230290B2 (en) | 2009-03-31 | 2013-03-14 | Boehringer Ingelheim International Gmbh | 1-heterocyclyl-1, 5-dihydro-pyrazolo [3, 4-d] pyrimidin-4-one derivatives and their use as PDE9A modulators |
| AU2010239266B2 (en) | 2009-04-22 | 2015-01-22 | Resverlogix Corp. | Novel anti-inflammatory agents |
| TWI419884B (zh) * | 2010-06-24 | 2013-12-21 | Univ Chang Gung | 苯并雜氧嗪酮衍生物，其製備方法以及包含有此等衍生物的藥學組成物 |
| AP2012006631A0 (en) | 2010-08-12 | 2012-12-31 | Boehringer Ingelheim Int | 6-Cycloalkyl-1, 5-dihydro-pyrazolo[3,4-D] pyrimidin-4-one derivatives and their use as PDE9A inhibitors |
| WO2012088266A2 (en) | 2010-12-22 | 2012-06-28 | Incyte Corporation | Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3 |
| US8809345B2 (en) | 2011-02-15 | 2014-08-19 | Boehringer Ingelheim International Gmbh | 6-cycloalkyl-pyrazolopyrimidinones for the treatment of CNS disorders |
| AR086168A1 (es) | 2011-04-20 | 2013-11-27 | Novartis Ag | Procesos para la elaboracion de depsipeptidos macrociclicos e intermediarios |
| US8680054B2 (en) | 2011-04-20 | 2014-03-25 | Novartis Ag | Suspension type topical formulations comprising cyclic depsipeptide |
| PT2773354T (pt) | 2011-11-01 | 2019-07-17 | Resverlogix Corp | Formulações orais de libertação imediata para quinazolinonas substituídas |
| JP6120941B2 (ja) | 2012-03-16 | 2017-04-26 | アクシキン ファーマシューティカルズ インコーポレーテッド | ３，５−ジアミノピラゾールキナーゼ阻害剤 |
| UA125503C2 (uk) | 2012-06-13 | 2022-04-13 | Інсайт Холдинґс Корпорейшн | Заміщені трициклічні сполуки як інгібітори fgfr |
| US9388185B2 (en) | 2012-08-10 | 2016-07-12 | Incyte Holdings Corporation | Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors |
| US9067978B2 (en) | 2012-10-09 | 2015-06-30 | Novartis Ag | Solution phase processes for the manufacture of macrocyclic depsipeptides and new intermediates |
| US8987413B2 (en) | 2012-10-09 | 2015-03-24 | Novartis Ag | Aldehyde acetal based processes for the manufacture of macrocyclic depsipeptides and new intermediates |
| US9765039B2 (en) | 2012-11-21 | 2017-09-19 | Zenith Epigenetics Ltd. | Biaryl derivatives as bromodomain inhibitors |
| WO2014080290A2 (en) | 2012-11-21 | 2014-05-30 | Rvx Therapeutics Inc. | Cyclic amines as bromodomain inhibitors |
| US9266892B2 (en) | 2012-12-19 | 2016-02-23 | Incyte Holdings Corporation | Fused pyrazoles as FGFR inhibitors |
| EP2935253B1 (en) | 2012-12-21 | 2018-08-01 | Zenith Epigenetics Ltd. | Novel heterocyclic compounds as bromodomain inhibitors |
| MY181497A (en) | 2013-04-19 | 2020-12-23 | Incyte Holdings Corp | Bicyclic heterocycles as fgfr inhibitors |
| NZ631142A (en) | 2013-09-18 | 2016-03-31 | Axikin Pharmaceuticals Inc | Pharmaceutically acceptable salts of 3,5-diaminopyrazole kinase inhibitors |
| SMT202000557T1 (it) | 2014-01-23 | 2020-11-10 | Sixera Pharma Ab | Derivati di benzoassazinone per il trattamento di malattie della pelle |
| ES2834851T3 (es) * | 2014-01-23 | 2021-06-18 | Sixera Pharma Ab | Nuevos inhibidores de calicreína 7 |
| US10851105B2 (en) | 2014-10-22 | 2020-12-01 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
| KR102034202B1 (ko) | 2014-12-23 | 2019-10-18 | 에스엠에이 세라퓨틱스 아이엔씨. | 3,5-디아미노피라졸 키나제 억제제 |
| CR20170390A (es) | 2015-02-20 | 2017-10-23 | Incyte Holdings Corp | Heterociclos biciclicos como inhibidores de fgfr |
| MA41551A (fr) | 2015-02-20 | 2017-12-26 | Incyte Corp | Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4 |
| US9580423B2 (en) | 2015-02-20 | 2017-02-28 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
| JP6903585B2 (ja) | 2015-03-13 | 2021-07-14 | レスバーロジックス コーポレイション | 補体関連疾患の治療のための組成物および治療方法 |
| AR111960A1 (es) | 2017-05-26 | 2019-09-04 | Incyte Corp | Formas cristalinas de un inhibidor de fgfr y procesos para su preparación |
| CA3078945A1 (en) * | 2017-10-09 | 2019-04-18 | Nuvation Bo Inc. | Heterocyclic compounds and uses thereof |
| EP3694861A4 (en) | 2017-10-09 | 2021-05-19 | Nuvation Bio Inc. | HETEROCYCLIC COMPOUNDS AND USES THEREOF |
| CN108421034A (zh) * | 2018-04-24 | 2018-08-21 | 济南磐升生物技术有限公司 | 激肽释放酶7在皮肤创伤愈合中的应用 |
| BR112020022392A2 (pt) | 2018-05-04 | 2021-02-02 | Incyte Corporation | formas sólidas de um inibidor de fgfr e processos para preparação das mesmas |
| PE20210919A1 (es) | 2018-05-04 | 2021-05-19 | Incyte Corp | Sales de un inhibidor de fgfr |
| TWI803696B (zh) | 2018-09-14 | 2023-06-01 | 日商橘生藥品工業股份有限公司 | 次黃嘌呤化合物 |
| US11628162B2 (en) | 2019-03-08 | 2023-04-18 | Incyte Corporation | Methods of treating cancer with an FGFR inhibitor |
| AU2020271837A1 (en) | 2019-04-09 | 2021-11-18 | Nuvation Bio Inc. | Heterocyclic compounds and uses thereof |
| US11591329B2 (en) | 2019-07-09 | 2023-02-28 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
| EP4037687B1 (en) | 2019-10-01 | 2025-10-29 | Molecular Skin Therapeutics, Inc. | Benzoxazinone compounds as klk5/7 dual inhibitors |
| US12122767B2 (en) | 2019-10-01 | 2024-10-22 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
| GEP20247679B (en) | 2019-10-14 | 2024-10-10 | Incyte Corp | Bicyclic heterocycles as fgfr inhibitors |
| WO2021076728A1 (en) | 2019-10-16 | 2021-04-22 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| PE20221504A1 (es) | 2019-12-04 | 2022-09-30 | Incyte Corp | Derivados de un inhibidor de fgfr |
| JP7720840B2 (ja) | 2019-12-04 | 2025-08-08 | インサイト・コーポレイション | Ｆｇｆｒ阻害剤としての三環式複素環 |
| WO2021146424A1 (en) | 2020-01-15 | 2021-07-22 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| JP7502945B2 (ja) * | 2020-09-08 | 2024-06-19 | 花王株式会社 | デリケートエリアのかぶれの検査方法 |
| TW202304459A (zh) | 2021-04-12 | 2023-02-01 | 美商英塞特公司 | 包含ｆｇｆｒ抑制劑及ｎｅｃｔｉｎ－４靶向劑之組合療法 |
| JP2024520154A (ja) | 2021-06-01 | 2024-05-21 | シクセラ・ファーマ・アーベー | ６－エトキシ－７－メトキシ－２－（２－メチルスルファニルフェニル）－３，１－ベンゾオキサジン－４－オンの水中油型乳剤 |
| TW202313611A (zh) | 2021-06-09 | 2023-04-01 | 美商英塞特公司 | 作為ｆｇｆｒ抑制劑之三環雜環 |
| CA3220155A1 (en) | 2021-06-09 | 2022-12-15 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
| WO2023250321A1 (en) * | 2022-06-21 | 2023-12-28 | Dana-Farber Cancer Institute, Inc. | Fused bicyclic egfr inhibitors and methods of use thereof |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1153994A (en) * | 1965-07-21 | 1969-06-04 | Aspro Nicholas Ltd | Hydroxyphenyl Anthranilic Acid Derivatives Capable of Absorbing 'Ultra-Violet Light and Compositions containing them |
| FR2121341A1 (en) | 1971-01-04 | 1972-08-25 | Ferlux | 2-substd-3,1-benzoxazin-4-ones - antiinflammatories, analgesics sedatives and diuretics |
| IT1050750B (it) * | 1975-12-05 | 1981-03-20 | Erba Carlo Spa | Derivati della 3.4 di idro chinazolina |
| JPS5576868A (en) | 1978-12-01 | 1980-06-10 | Hisamitsu Pharmaceut Co Inc | Novel 3,1-bezoxazine derivative |
| GB8817651D0 (en) * | 1988-07-25 | 1988-09-01 | Smith Kline French Lab | Chemical compounds |
| FI912995A7 (fi) | 1988-12-21 | 1991-06-19 | Upjohn Co | Antiateroskleroottisia ja antitromboottisia 1-bentsopyran-4-oneja ja 2 -amino-1,3-bentsoksatsin-4-oneja |
| JPH07316056A (ja) * | 1990-02-15 | 1995-12-05 | Teijin Ltd | エラスターゼ阻害用医薬組成物 |
| JP2685648B2 (ja) * | 1990-02-15 | 1997-12-03 | 帝人株式会社 | ４ｈ−３．１−ベンズオキサジン−４−オン化合物 |
| ES2106783T3 (es) * | 1990-06-20 | 1997-11-16 | Upjohn Co | 1-benzopiran-4-onas y 2-amino-1,3-benzoxacin-4-onas antiarterosclerosis y antitromboticas. |
| US5480883A (en) * | 1991-05-10 | 1996-01-02 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase |
| EP0584222B1 (en) * | 1991-05-10 | 1997-10-08 | Rhone-Poulenc Rorer International (Holdings) Inc. | Bis mono-and bicyclic aryl and heteroaryl compounds which inhibit egf and/or pdgf receptor tyrosine kinase |
| US5346886A (en) * | 1993-11-15 | 1994-09-13 | John Lezdey | Topical α-1-antitrypsin, non-aqueous lipid miscible, benzalkonium chloride compositions for treating skin |
| AU1375000A (en) * | 1998-11-26 | 2000-06-13 | Novo Nordisk A/S | Heterocyclic compounds regulating clotting |
| AU7125700A (en) * | 1999-09-10 | 2001-04-10 | Procter & Gamble Company, The | Enzyme inhibitors |
| ATE515940T1 (de) | 2001-02-09 | 2011-07-15 | Torbjoern Egelrud | Scce transgene mäuse und deren verwendung als modell für menschliche krankheiten |
| WO2003007955A2 (en) * | 2001-07-20 | 2003-01-30 | Cancer Research Technology Limited | Biphenyl apurinic/apyrimidinic site endonuclease inhibitors to treat cancer |
| GB2410025B (en) * | 2002-10-03 | 2007-03-28 | Inst Med Molecular Design Inc | Quinazolin-4-one derivatives |
| AU2003291761A1 (en) * | 2002-11-04 | 2004-06-07 | Nps Pharmaceuticals, Inc. | Quinazolinone compounds as calcilytics |
| PE20040950A1 (es) * | 2003-02-14 | 2005-01-01 | Theravance Inc | DERIVADOS DE BIFENILO COMO AGONISTAS DE LOS RECEPTORES ADRENERGICOS ß2 Y COMO ANTAGONISTAS DE LOS RECEPTORES MUSCARINICOS |
-
2004
- 2004-06-07 WO PCT/DK2004/000388 patent/WO2004108139A2/en not_active Ceased
- 2004-06-07 SI SI200431406T patent/SI1631295T1/sl unknown
- 2004-06-07 KR KR1020117022051A patent/KR101205257B1/ko not_active Expired - Fee Related
- 2004-06-07 DE DE602004025803T patent/DE602004025803D1/de not_active Expired - Lifetime
- 2004-06-07 ES ES04736195T patent/ES2341545T3/es not_active Expired - Lifetime
- 2004-06-07 JP JP2006508134A patent/JP5044214B2/ja not_active Expired - Fee Related
- 2004-06-07 KR KR1020057023349A patent/KR101099409B1/ko not_active Expired - Fee Related
- 2004-06-07 PL PL04736195T patent/PL1631295T3/pl unknown
- 2004-06-07 PT PT04736195T patent/PT1631295E/pt unknown
- 2004-06-07 DK DK04736195.1T patent/DK1631295T3/da active
- 2004-06-07 NZ NZ543636A patent/NZ543636A/en not_active IP Right Cessation
- 2004-06-07 CN CN2007101613027A patent/CN101152185B/zh not_active Expired - Fee Related
- 2004-06-07 CA CA2525383A patent/CA2525383C/en not_active Expired - Fee Related
- 2004-06-07 EP EP04736195A patent/EP1631295B1/en not_active Expired - Lifetime
- 2004-06-07 AT AT04736195T patent/ATE459359T1/de active
- 2004-06-07 US US10/559,322 patent/US7872052B2/en not_active Expired - Lifetime
-
2006
- 2006-01-06 NO NO20060091A patent/NO20060091L/no not_active Application Discontinuation
-
2010
- 2010-05-21 CY CY20101100450T patent/CY1110084T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2006526581A5 (enExample) | ||
| CA2525383A1 (en) | Use of heterocyclic compounds as scce inhibitors | |
| DK172070B1 (da) | Benzonaphthalen-derivater, fremgangsmåde til deres fremstilling og deres anvendelse samt framaceutiske og kosmetiske præparater deraf | |
| DE69626684T2 (de) | Metallproteinasehemmer, diesen enthaltende pharmazeutische zusammensetzung und dessen pharmazeutische verwendung und verfahren zu ihrer herstellung | |
| JPH0784437B2 (ja) | 複素環レチノイド | |
| US4800211A (en) | 5-methylthio-3-hydroxybenzo [b]thiophene-2-carboxamide derivatives as cyclooxygenase and lipoxygenase inhibitors | |
| US20030073712A1 (en) | Cytoprotective compounds, pharmaceutical and cosmetic formulations, and methods | |
| AU2002319677A1 (en) | Cytoprotective compounds, pharmaceutical and cosmetic formulations, and methods | |
| WO2017129897A1 (fr) | Inhibiteurs nlrp3 pour le traitement des pathologies cutanées inflammatoires | |
| CA2060750A1 (fr) | Derives bicycliques azotes, leur procede de preparation, nouveaux intermediaires obtenus, leur application a titre de medicaments et les compositions pharmaceutiques les renfermant | |
| CA2022570A1 (en) | Diarylacetylenes, the preparation and use thereof | |
| CN105828798A (zh) | 烷基酰胺基噻唑在用于预防和处理敏感性皮肤的美容或皮肤病学制剂中的用途 | |
| JP2579339B2 (ja) | 多環複素環誘導体、その製法および人・動物医薬 | |
| JPS63500310A (ja) | 新規カルボン酸誘導体、その製法、その使用並びにこの化合物を含有する医薬品 | |
| JP2018532692A5 (enExample) | ||
| JP2602629B2 (ja) | 芳香族カルボン酸誘導体及び皮膚・粘膜治療剤 | |
| PT1637527E (pt) | Modulador do receptor de canabinóides | |
| EP1098891B1 (de) | Polycyclische thiazolidin-2-yliden amine, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel | |
| JP2005530840A (ja) | コウジ酸誘導体及びその製造方法 | |
| JPH11507960A (ja) | 二環式芳香族化合物、これらを含有する組成物及びその使用 | |
| WO2014164886A1 (en) | Prostanoid receptor agonist compounds and their use | |
| AU737454B2 (en) | Method for inhibiting the growth of mammalian cells | |
| JP2002538101A (ja) | 肥満症を予防または治療するための薬剤の製造における多環式チアゾール系の使用 | |
| TW200306814A (en) | Dihydrobenzofuran and dihydrobenzothiophene 2,4-pentadienoic acid derivatives having selective activity for retinoid X(RXR)receptors | |
| ZA200106198B (en) | Polycyclic 2-amino-thiazole systems, method for the production thereof and medicament containing said compounds. |